Below, we present the role of the PD-L1 pathway in cancer immune evasion, the role of RKIP in anti-tumor immune activation, the signaling cross-talks between RKIP and PD-L1 expressions, and targeted therapeutic strategies to avoid immune evasion. This evidence concerns the gene PEBP1 and cancer.